GIST

clinical topic updates

by Jonathan C. Trent, MD, PhD

Newer targets and combinations are being explored to help bridge the gap for patients with advanced gastrointestinal stromal tumors (GIST). Our fea......READ MORE

clinical topic updates

by Richard F. Riedel, MD

Wild-type gastrointestinal stromal tumors (GIST) lack KIT and PDGFRA mutations, but they may harbor other potentially targetable alterations. Our f......READ MORE

clinical topic updates

by Arun Singh, MD

The recent US Food and Drug Administration (FDA) approvals of 2 novel tyrosine kinase inhibitors (TKIs), avapritinib and ripretinib, may help to ov......READ MORE

clinical topic updates

by Michael C. Heinrich, MD

Clinical research on the treatment of advanced gastrointestinal stromal tumors (GIST) has led to the US Food and Drug Administration (FDA) approval......READ MORE

clinical topic updates

by Arun Singh, MD

Tyrosine kinase inhibitors (TKIs) for gastrointestinal stromal tumors (GIST) are effective; however, resistance typically develops. In addition to ......READ MORE